Similar articles

• The ongoing regulation of generic drugs.

  Frank RG. Frank RG. N Engl J Med. 2007 Nov 15;357(20):1993-6. doi: 10.1056/NEJMp078193. N Engl J Med. 2007. PMID: 18003956 No abstract available.
• Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.

  Gitter DM. Gitter DM. Seton Hall Law Rev. 2011;41(2):559-92. Seton Hall Law Rev. 2011. PMID: 21739759 No abstract available.
• A precarious balancing act--the role of the FDA as protector of public health and industry wealth.

  McCabe AR. McCabe AR. Suffolk Univ Law Rev. 2003;36(3):787-819. Suffolk Univ Law Rev. 2003. PMID: 16493844 No abstract available.
• Pharmaceutical policies in Canada: another example of federal-provincial discord.

  Anis AH. Anis AH. CMAJ. 2000 Feb 22;162(4):523-6. CMAJ. 2000. PMID: 10701389 Free PMC article. Review.
• Patent lifecycle management strategies in open innovation projects.

  Lee Y, Fong EA. Lee Y, et al. Drug Discov Today. 2020 Oct;25(10):1782-1785. doi: 10.1016/j.drudis.2020.06.019. Epub 2020 Jun 24. Drug Discov Today. 2020. PMID: 32592662 Review.